According to Roth Capital Partners, biopharma Company Imugene Limited (ASX:IMU) is suitably funded through enough cash to finance its operations through FY2022. Moreover, the brokerage acknowledged IMU’s clinical progress of multiple vaccines, such as HER-Vaxx and PD1-Vaxx, despite COVID-19-related enrolment headwinds.
The HER-Vaxx trial is targeting HER-2 positive gastric cancer, while the PD1-Vaxx is a vaccine designed to treat tumours such as lung cancer.
Notably, IMU had declared cash reserves of A$32.8 million with zero debt in the previous month.
Further, Roth Capital looks forward to final HER-Vaxx results and the commencement of the clinical programs of oncolytic virus candidates, VAXinia and CHECKvacc, in the US.